These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 25185137

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 3. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.
    Calmy A, Carey D, Mallon PW, Wand H, Law M, Cooper DA, Carr A, INITIO Trial International Co-ordinating Committee, HAMA study coordination team.
    HIV Med; 2008 Feb 01; 9(2):101-10. PubMed ID: 18257772
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.
    HIV Med; 2006 Jan 01; 7(1):38-45. PubMed ID: 16313291
    [Abstract] [Full Text] [Related]

  • 9. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N, Bagheri H, Sommet A, Delpierre C, Marion-Latard F, Massip P, Aquilina C, Bonnet E, Obadia M, Labau E, Montastruc JL, Bernard J.
    Pharmacotherapy; 2006 Feb 01; 26(2):154-61. PubMed ID: 16466321
    [Abstract] [Full Text] [Related]

  • 10. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A.
    Diabetes Care; 2007 Jan 01; 30(1):113-9. PubMed ID: 17192343
    [Abstract] [Full Text] [Related]

  • 11. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.
    Mallon PW, Miller J, Cooper DA, Carr A.
    AIDS; 2003 May 02; 17(7):971-9. PubMed ID: 12700446
    [Abstract] [Full Text] [Related]

  • 12. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents.
    Viganò A, Mora S, Manzoni P, Schneider L, Beretta S, Molinaro M, di Natale B, Brambilla P.
    J Clin Endocrinol Metab; 2005 Jul 01; 90(7):4075-80. PubMed ID: 15840750
    [Abstract] [Full Text] [Related]

  • 15. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy.
    Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Motsinger AA, Kallianpur AR, AIDS Clinical Trials Group 384 and A5005s Study Teams.
    J Infect Dis; 2008 Mar 15; 197(6):858-66. PubMed ID: 18419350
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults.
    Jantarapakde J, Phanuphak N, Chaturawit C, Pengnonyang S, Mathajittiphan P, Takamtha P, Dungjun N, Pinyakorn S, Pima W, Prasithsirikul W, Phanuphak P.
    AIDS Patient Care STDS; 2014 Jul 15; 28(7):331-40. PubMed ID: 24914459
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 15; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 19. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
    Blümer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, Yki-Jarvinen H, Danner SA, Reiss P, Sauerwein HP.
    AIDS; 2008 Jan 11; 22(2):227-36. PubMed ID: 18097225
    [Abstract] [Full Text] [Related]

  • 20. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, Da Silva B.
    Clin Infect Dis; 2005 Oct 15; 41(8):1186-95. PubMed ID: 16163639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.